Merck (MRK) Analysts Point to +15% Upside Toward $170 Target

Key Takeaways

• The central target of $170 reflects the average of verified analyst price targets above the current price, implying roughly 15% upside from recent trading near $148.
• Across 28 analysts tracked by S&P Global, the overall average sits near $161.50 (about 9% above the price), so the $170 figure averages only those targets exceeding the current level and rounds to a clean number.
• Individual targets range widely from roughly $105 to $186, highlighting sharp differences in views on how Merck’s oncology pipeline might offset upcoming patent expirations.
• Key positive drivers include encouraging Phase 3 results for the intismeran autogene cancer vaccine along with a diversified late-stage pipeline featuring sac-TMT and tulisokibart.
• The main risks center on the 2028 loss of exclusivity for blockbuster drug Keytruda, softer Gardasil demand in China, and valuation considerations.
• Additional detail is available on Major News, Today's Price Move, Forecast, and Earnings pages.
• For a broader automated market perspective, review Trending AI Robots.

Analyst Price Targets and Consensus

Merck & Co., Inc. (MRK), known outside the U.S. and Canada as MSD, draws its target from extensive sell-side coverage. Roughly 28 analysts followed by S&P Global maintain a consensus “Buy” rating, though individual targets stretch from about $105 (Bernstein) to $186, underscoring divided opinions on the outlook.

The broad average of all targets lands near $161.50, or roughly 9% above the latest price. Because that margin falls short of a clear 10% threshold, the central target here averages only the figures above the current price, yielding about $167 before rounding to $170. This remains a derived figure rather than an official published consensus.

Bullish targets cluster between $160 and $180. Morgan Stanley upgraded to Overweight and lifted its target to $179, while Scotiabank ($180), J.P. Morgan and UBS ($175 each), Wells Fargo, BMO Capital, and Guggenheim ($170 each) all highlight the cancer vaccine and oncology pipeline. More cautious calls include Cantor Fitzgerald’s Hold at $155, DZ Bank’s Hold at $153, RBC Capital’s neutral stance at $140 citing valuation, and Citi’s $125 target.

Current Market Position and Path to the Target

Merck recently traded near $147.76, so a move to $170 would represent a gain of about 15%—a meaningful but realistic step for a large-cap that has already rallied sharply over the past year. The stock has roughly doubled from its 2025 lows as investors revisited its post-Keytruda growth narrative.

Reaching that level depends more on execution than valuation alone. While 2026 earnings face pressure from acquisition-related charges, attention centers on whether new oncology assets—the intismeran autogene cancer vaccine with Moderna, sacituzumab tirumotecan (sac-TMT), and tulisokibart—can restore growth ahead of Keytruda’s 2028 patent cliff. A sustained advance toward $170 would likely need positive data readouts and signs these programs can scale commercially.

Factors That Could Support a Move Higher

Positive Phase 3 data for intismeran autogene in melanoma has bolstered the bullish case, with Morgan Stanley noting Merck now has a credible path beyond Keytruda. The completed Terns Pharmaceuticals acquisition adds TERN-701 for chronic myeloid leukemia, adding further pipeline diversity. Merck’s scale, cash flow, and catalyst-rich late-stage portfolio—covering sac-TMT, tulisokibart, and a once-weekly HIV therapy—give analysts reasons to raise targets. A roughly 68% “Buy/Strong Buy” tilt shows broad constructive sentiment.

Risks That Could Keep the Target Out of Reach

The primary hurdle remains Keytruda’s 2028 loss of exclusivity, which endangers a franchise responsible for a large share of revenue. RBC Capital has called Merck’s valuation “unprecedented” for a company facing a major LOE in roughly two years, even while recognizing pipeline progress. Softening Gardasil demand in China, uncertainty around the commercial scale of the cancer-vaccine opportunity, and projected earnings softness near 2027 all weigh on enthusiasm. Disappointing pipeline data or slower uptake could leave shares consolidating well below $170.

Technical Levels and Market Structure

Merck’s longer-term trend remains upward, with the stock more than doubling from its 2025 lows. The $150 area serves as a notable round-number psychological level the stock has tested, and a decisive, sustained close above it would strengthen the constructive setup. On the downside, a move back below the $140 zone would suggest fading momentum. These technical markers matter less than fundamental catalysts for a stock driven mainly by data readouts.

Time Horizon and Items to Watch

Analyst targets generally reflect a roughly 12-month research horizon, though firms adjust views as new data arrives. Near-term focus areas include additional sac-TMT and tulisokibart readouts, further intismeran autogene updates, Gardasil demand trends in China, and the path of 2027 earnings as the Keytruda patent expiration nears. Earnings reports and any target revisions from the firms mentioned will also draw attention.

Using AI Tools in Research

I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. From what I see, it helps surface comparable names quickly when evaluating pipeline-driven pharma names like Merck.

AI Daily Buy/Sell Signals

I’ve found Tickeron’s AI Daily Buy/Sell Signals useful for tracking momentum shifts across thousands of stocks and ETFs. The signals draw on artificial intelligence to monitor technical behavior and market conditions, offering a practical way to complement fundamental research on names like Merck without manually scanning charts. The dashboard can help spot changing trends and manage positions more efficiently when pipeline catalysts are in focus.

Final Assessment

Can MRK reach $170? The target is achievable in principle as the average of analyst targets already above the current price, yet it is not a forecast. A roughly 15% move would require continued positive pipeline data and growing confidence that Merck can offset Keytruda revenue before 2028. Support stems from the cancer-vaccine readout and a deep late-stage portfolio, while the wide $105–$186 range illustrates genuine analyst disagreement on valuation and execution risk. Investors should monitor data readouts, Gardasil trends, and earnings revisions rather than treat $170 as a certainty.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Allana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume